Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-11095-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Yiming Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 330106, …. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Strategic Priority Research Program of the Chinese Academy of sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The p53 Y220C mutation, a prevalent structural variant in human cancers, compromises DNA binding and tumor suppressor functions by destabilizing the protein structure. Leveraging a combined approach of structure-based virtual screening, molecular dynamics simulations, and in vitro assays, we have identified C8, a racemic compound with an indole core and α, β-unsaturated carbonyl groups, as a covalent stabilizer for p53 Y220C. Protein thermal shift and homogeneous time-resolved fluorescence assays confirmed that C8 and its analogs selectively bind to p53 Y220C and restore its DNA binding ability. Subsequent molecular dynamics simulations and structure-activity relationship analyses showed that both enantiomers of C8 form covalent bonds with Cys124 and Cys220, stabilizing the mutant structure. C8 and its analogs emerge as promising lead candidates for restoring the Y220C mutant's transcriptional function, highlights the potential of this scaffold for further optimization into p53 Y220C-targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 330106, China.
- State Key Laboratory of Drug Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.
- School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
- School of Pharmacy, East China Normal University, Shanghai, 200241, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, China.
Förderung
- National Key Research and Development Program of China
- Strategic Priority Research Program of the Chinese Academy of sciences
- National Natural Science Foundation of China
- SIMM-SHUTCM Traditional Chinese Medicine Innovation Joint Research Program
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- the Youth Innovation Promotion Association CAS
- Large-scale Protein Preparation System at the National Facility for Protein Science in Shanghai (NFPS), Shanghai Advanced Research Institute, Chinese Academy o…
Zitieren
APA
Wen, Y., Xu, P., Chen, Y., Meng, J., Zheng, M., Zhang, S., Teng, D., & Li, X. (2025). Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods. Molecular Diversity. https://doi.org/10.1007/s11030-024-11095-1
Vancouver
Wen Y, Xu P, Chen Y, Meng J, Zheng M, Zhang S, et al. Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods. Molecular Diversity. 2025. doi:10.1007/s11030-024-11095-1
BibTeX
@article{Wen2025,
author = {Wen, Yiming and Xu, Peijia and Chen, Yijie and Meng, Jingyi and Zheng, Mingyue and Zhang, Sulin and Teng, Dan and Li, Xutong},
title = {Discovery of novel covalent stabilizers for p53 Y220C using structure-based drug discovery methods},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-11095-1}
}
EUVIMED